Clinical significance of MDM2 as a tumor biomarker
Authors:
- 8 June 2012
- journal article
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 11 (6) , 356-360
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese populationBMC Cancer, 2010
- Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer CellsClinical Cancer Research, 2009
- Association ofTP53andMDM2polymorphisms with survival in bladder cancer patients treated with chemoradiotherapyCancer Science, 2009
- Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysisBreast Cancer Research and Treatment, 2009
- MDM2 309 T/G polymorphism is associated with lung cancer risk among AsiansEuropean Journal of Cancer, 2009
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer TherapyAnnual Review of Pharmacology and Toxicology, 2009
- MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphismBMC Cancer, 2008
- Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2Molecular Cancer Therapeutics, 2006
- MDM2 protein expression is a negative prognostic marker in breast carcinomaLaboratory Investigation, 2005
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004